These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

111 related articles for article (PubMed ID: 2528057)

  • 1. Activity of thymidylate synthetase and its inhibition by 5-fluorouracil in highly enzyme-overproducing cells resistant to 10-propargyl-5,8-dideazafolate.
    Danenberg KD; Danenberg PV
    Mol Pharmacol; 1989 Aug; 36(2):219-23. PubMed ID: 2528057
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Increased thymidylate synthase in L1210 cells possessing acquired resistance to N10-propargyl-5,8-dideazafolic acid (CB3717): development, characterization, and cross-resistance studies.
    Jackman AL; Alison DL; Calvert AH; Harrap KR
    Cancer Res; 1986 Jun; 46(6):2810-5. PubMed ID: 2938731
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Activity of the thymidylate synthase inhibitor 2-desamino-N10-propargyl-5,8-dideazafolic acid and related compounds in murine (L1210) and human (W1L2) systems in vitro and in L1210 in vivo.
    Jackman AL; Taylor GA; O'Connor BM; Bishop JA; Moran RG; Calvert AH
    Cancer Res; 1990 Sep; 50(17):5212-8. PubMed ID: 2386929
    [TBL] [Abstract][Full Text] [Related]  

  • 4. In vivo kinetics of thymidylate synthetase inhibition of 5-fluorouracil-sensitive and -resistant murine colon adenocarcinomas.
    Spears CP; Shahinian AH; Moran RG; Heidelberger C; Corbett TH
    Cancer Res; 1982 Feb; 42(2):450-6. PubMed ID: 6173112
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Thymidylate synthase overproduction and gene amplification in fluorodeoxyuridine-resistant human cells.
    Berger SH; Jenh CH; Johnson LF; Berger FG
    Mol Pharmacol; 1985 Nov; 28(5):461-7. PubMed ID: 2932632
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Novel mechanism(s) of resistance to 5-fluorouracil in human colon cancer (HCT-8) sublines following exposure to two different clinically relevant dose schedules.
    Aschele C; Sobrero A; Faderan MA; Bertino JR
    Cancer Res; 1992 Apr; 52(7):1855-64. PubMed ID: 1532346
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Drug-resistant variants of Escherichia coli thymidylate synthase: effects of substitutions at Pro-254.
    Fantz C; Shaw D; Jennings W; Forsthoefel A; Kitchens M; Phan J; Minor W; Lebioda L; Berger FG; Spencer HT
    Mol Pharmacol; 2000 Feb; 57(2):359-66. PubMed ID: 10648646
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Human lymphoblastoid cells with acquired resistance to C2-desamino-C2-methyl-N10-propargyl-5,8-dideazafolic acid: a novel folate-based thymidylate synthase inhibitor.
    O'Connor BM; Jackman AL; Crossley PH; Freemantle SE; Lunec J; Calvert AH
    Cancer Res; 1992 Mar; 52(5):1137-43. PubMed ID: 1737372
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A naturally occurring variation in thymidylate synthase structure is associated with a reduced response to 5-fluoro-2'-deoxyuridine in a human colon tumor cell line.
    Berger SH; Barbour KW; Berger FG
    Mol Pharmacol; 1988 Oct; 34(4):480-4. PubMed ID: 2971872
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cellular pharmacology and in vivo activity of a new anticancer agent, ZD9331: a water-soluble, nonpolyglutamatable, quinazoline-based inhibitor of thymidylate synthase.
    Jackman AL; Kimbell R; Aherne GW; Brunton L; Jansen G; Stephens TC; Smith MN; Wardleworth JM; Boyle FT
    Clin Cancer Res; 1997 Jun; 3(6):911-21. PubMed ID: 9815766
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Thymidylate synthase level as the main predictive parameter for sensitivity to 5-fluorouracil, but not for folate-based thymidylate synthase inhibitors, in 13 nonselected colon cancer cell lines.
    van Triest B; Pinedo HM; van Hensbergen Y; Smid K; Telleman F; Schoenmakers PS; van der Wilt CL; van Laar JA; Noordhuis P; Jansen G; Peters GJ
    Clin Cancer Res; 1999 Mar; 5(3):643-54. PubMed ID: 10100718
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacogenomic dissection of resistance to thymidylate synthase inhibitors.
    Wang W; Marsh S; Cassidy J; McLeod HL
    Cancer Res; 2001 Jul; 61(14):5505-10. PubMed ID: 11454699
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of thymidylate synthase (TS) protein up-regulation after exposure to TS inhibitors in normal and tumor cell lines and tissues.
    Welsh SJ; Titley J; Brunton L; Valenti M; Monaghan P; Jackman AL; Aherne GW
    Clin Cancer Res; 2000 Jun; 6(6):2538-46. PubMed ID: 10873110
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Thymidylate synthase gene amplification in fluorodeoxyuridine-resistant mouse cell lines.
    Jenh CH; Geyer PK; Baskin F; Johnson LF
    Mol Pharmacol; 1985 Jul; 28(1):80-5. PubMed ID: 2991733
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Determinants of cytotoxicity with prolonged exposure to fluorouracil in human colon cancer cells.
    Ren Q; Van Groeningen CJ; Hardcastle A; Aherne GW; Geoffroy F; Allegra CJ; Johnston PG; Grem JL
    Oncol Res; 1997; 9(2):77-88. PubMed ID: 9167189
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Creation and characterization of 5-fluorodeoxyuridine-resistant Arg50 loop mutants of human thymidylate synthase.
    Landis DM; Heindel CC; Loeb LA
    Cancer Res; 2001 Jan; 61(2):666-72. PubMed ID: 11212266
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Increased levels of thymidylate synthetase in cells exposed to 5-fluorouracil.
    Washtien WL
    Mol Pharmacol; 1984 Jan; 25(1):171-7. PubMed ID: 6708932
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Determinants of activity of the antifolate thymidylate synthase inhibitors Tomudex (ZD1694) and GW1843U89 against mono- and multilayered colon cancer cell lines under folate-restricted conditions.
    Peters GJ; Smitskamp-Wilms E; Smid K; Pinedo HM; Jansen G
    Cancer Res; 1999 Nov; 59(21):5529-35. PubMed ID: 10554030
    [TBL] [Abstract][Full Text] [Related]  

  • 19. bcl-2 modulation of apoptosis induced by anticancer drugs: resistance to thymidylate stress is independent of classical resistance pathways.
    Fisher TC; Milner AE; Gregory CD; Jackman AL; Aherne GW; Hartley JA; Dive C; Hickman JA
    Cancer Res; 1993 Jul; 53(14):3321-6. PubMed ID: 8324744
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Synergistic growth inhibition of rat hepatoma cells exposed in vitro to N10-propargyl-5,8-dideazafolate with methotrexate or the lipophilic antifolates trimetrexate or metoprine.
    Galivan J; Nimec Z; Rhee M
    Cancer Res; 1987 Oct; 47(20):5256-60. PubMed ID: 2958130
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.